Humasis Co. Ltd (205470) - Total Liabilities

Latest as of September 2025: ₩90.75 Billion KRW ≈ $61.50 Million USD

Based on the latest financial reports, Humasis Co. Ltd (205470) has total liabilities worth ₩90.75 Billion KRW (≈ $61.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Humasis Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Humasis Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Humasis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Humasis Co. Ltd asset portfolio.

Humasis Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Humasis Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Profound Medical Corp
TO:PRN
Canada CA$12.56 Million
104 Corporation
TW:3130
Taiwan NT$2.17 Billion
Lealea Enterprise Co Ltd
TW:1444
Taiwan NT$9.08 Billion
Piedmont Lithium Inc
AU:PLL
Australia AU$40.90 Million
Yesco Holdings Co. Ltd
KO:015360
Korea ₩978.22 Billion
Solar A/S
CO:SOLAR-B
Denmark Dkr4.30 Billion
Smart Parking Ltd
AU:SPZ
Australia AU$42.15 Million
Spok Holdings Inc
NASDAQ:SPOK
USA $52.93 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Humasis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Humasis Co. Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.49 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Humasis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Humasis Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Humasis Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩102.65 Billion
≈ $69.57 Million
+71.14%
2023-12-31 ₩59.98 Billion
≈ $40.65 Million
-50.35%
2022-12-31 ₩120.80 Billion
≈ $81.86 Million
-12.91%
2021-12-31 ₩138.71 Billion
≈ $94.00 Million
+611.03%
2020-12-31 ₩19.51 Billion
≈ $13.22 Million
-8.17%
2019-12-31 ₩21.24 Billion
≈ $14.40 Million
+16.93%
2018-12-31 ₩18.17 Billion
≈ $12.31 Million
+42.74%
2017-12-31 ₩12.73 Billion
≈ $8.63 Million
+906.96%
2016-12-31 ₩1.26 Billion
≈ $856.63K
-70.13%
2015-12-31 ₩4.23 Billion
≈ $2.87 Million
+1.78%
2014-12-31 ₩4.16 Billion
≈ $2.82 Million
--

About Humasis Co. Ltd

KQ:205470 Korea Medical Devices
Market Cap
$217.40 Million
₩320.79 Billion KRW
Market Cap Rank
#16325 Global
#592 in Korea
Share Price
₩2835.00
Change (1 day)
-3.57%
52-Week Range
₩682.00 - ₩4265.00
All Time High
₩8520.77
About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more